Lamivudine Accord (Lamivudine)

Lamivudine enters cells and is converted to its active triphosphate form. This active metabolite mimics natural nucleosides and is incorporated into viral DNA by reverse transcriptase, causing premature chain termination and preventing the virus from multiplying.

The specific dose of Lamivudine Accord is determined by the prescribing clinician based on the patient’s age, weight, renal function, and the overall treatment regimen. Only a qualified health professional should set the dosage and schedule.

Safety data for lamivudine in pregnancy and lactation are limited. It should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision must be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other NRTIs or drugs from different classes for optimal viral suppression. Compared with some older NRTIs, lamivudine generally has a favorable safety profile and lower mitochondrial toxicity, but resistance can develop if used as monotherapy.

Lamivudine Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain its stability.

Lamivudine Accord is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include lactic acidosis, severe hepatomegaly with steatosis, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, hypersensitivity reactions, and significant neutropenia. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Lamivudine Accord should be avoided in patients with known hypersensitivity to lamivudine or any of its excipients. It is also contraindicated in individuals with severe renal impairment who cannot be appropriately dose‑adjusted, and it should not be used as monotherapy due to the risk of resistance.